KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.
KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.